Limited Access to Mounjaro on NHS Sparks Concern Months After Launch in England

Despite the NHS officially beginning the phased roll-out of tirzepatide (marketed as Mounjaro) over two months ago, recent investigations reveal that less than half of England's population has access to the medication through their general practitioners (GPs). The initiative, aimed at tackling obesity and related health conditions, was launched on June 23, 2025, with NHS England and the National Institute for Health and Care Excellence (NICE) planning for a 12-year phased introduction. This long-term plan was designed to ensure sustainable integration of the drug, which is estimated to benefit approximately 3.4 million people.

However, data obtained via Freedom of Information requests shows that only 43% of the 42 commissioning bodies across the country have begun prescribing tirzepatide in accordance with the phased plan. NHS England projected that around 70% of eligible patients would seek treatment, yet only nine integrated care boards (ICBs) have confirmed receiving enough funding to cover at least that proportion.

Funding shortages are causing significant challenges. Several ICBs report that their allocated funds are insufficient, with some, like Coventry and Warwickshire, covering as little as 21% of their eligible population. Birmingham and Solihull ICB has funding for just over half, at 52%. Meanwhile, many practices have posted notices advising patients that they cannot currently access the medication, leading to confusion and frustration among potential users.

Experts warn that this underfunding and poor communication are creating distress for both patients and healthcare providers. The situation is likely to worsen as eligibility criteria expand annually and additional funding is necessary to meet the increasing demand. Notably, some ICBs are already considering stricter prescribing policies or rationing to manage limited resources.

The lack of adequate funding is also expected to have long-term implications. Researchers, including Jonathan Hazlehurst from the University of Birmingham, highlight that initial funding levels are far below projections—only around 10% of the targeted treatment number can be covered in the first year. This discrepancy delays access for those who could benefit most, especially individuals with urgent needs.

Advocates emphasize that equitable access is crucial, especially for people living with obesity who require evidence-based interventions to improve their health. The disconnect between national messaging and local implementation underscores the urgent need for improved planning and resource allocation.

NHS England declined to provide a comment at the time of publication. As the rollout continues, stakeholders call for enhanced transparency, increased funding, and clearer communication to ensure that the promising benefits of tirzepatide can reach all eligible patients effectively.

Source: https://medicalxpress.com/news/2025-09-england-access-mounjaro-nhs-months.html